News

Recommended tags

+ More Filters

Indication

Solid Tumors ^× Lung Cancer Prostate Cancer Ovarian Cancer

Product Candidates

BOXR1030 DCVAC/LuCa DCVAC/OvCa DCVAC/PCa nanrilkefusp alfa SOT102 ^× SOT106 SOT201

Release Type

Corporate Investments Partnering ^×

NEWS November 16, 2021

SOTIO Expands its Antibody-Drug Conjugate Pipeline with Exclusive Collaboration and License Agreement with LegoChem Biosciences

SOTIO Biotech licenses LegoChem Biosciences (LCB) technology for five new antibody-drug conjugate (ADC) programs
Rights to LCB’s ADC platform acquired for total of up to $1027.5 million payable based on certain developments and regulatory achievements, including upfront and near-term success dependent milestones worth up to $29.5 million
SOTIO will be responsible for the research, development, manufacturing and commercialization of the ADC products

SOTIO Biotech, a clinical stage immuno-oncology company owned by PPF Group, today announced an exclusive, target-specific license and option agreement with LegoChem Biosciences Inc. (LCB, KOSDAQ: 141080), a biotechnology company focused on developing its clinical-stage platform technology enabling antibody-drug conjugates (ADCs) with an excellent therapeutic index. SOTIO will obtain rights to deploy LCB’s ADC technology for up to five therapeutic programs targeting distinct tumor-associated antigens.

NEWS October 20, 2016

SOTIO and NBE-Therapeutics sign collaboration and license agreement for next-generation antibody-drug conjugates

Basel, Switzerland & Prague, Czech Republic – NBE-Therapeutics AG and SOTIO a.s. today announced that the companies have entered into a collaboration for the development of next-generation antibody-drug conjugates (ADCs) for improved cancer therapy. Under the agreement, NBE and SOTIO will collaborate on the discovery, non-clinical development and manufacturing of novel ADC products against undisclosed targets. The ADC products will be based on NBE’s proprietary antibody discovery and conjugation platforms, including NBE’s Transpo-mAb^TM antibody platform, its site-specific SMAC^TM conjugation technology and its novel ultra-potent toxin platform. SOTIO will have global responsibility for clinical development, registration and commercialization of the ADC products.

Cookie name	Description	Expiration
BCAPPSESSID3	The BCAPPSESSID3 cookie is native to PHP and enables websites to store serialised state data. It is used to establish a user session and to pass state data via a temporary cookie, which is commonly referred to as a session cookie.	14 days
SSC_COOKIE_*	This cookie stores your decision regarding the storage of cookies in your browser.	2 years

Cookie name	Description	Expiration
_ga	The GA cookie is set, when a person visits your website for the first time. Google Analytics sends the client ID with each hit in order to associate hits with a user. A GA cookie can exist only on the device and browser where it has been set.	2 years
_gid	This cookie is installed by Google Analytics. The cookie is used to store information of how visitors use a website and helps in creating an analytics report of how the website is doing.	24 hours
_gat_gtag_UA_27872723_1	This cookie is used to throttle request rate. These are third party cookies that are placed on your device to allow us to use the Google Analytics service. These cookies are used to collect information about how visitors use our website. We use this information to compile reports and to help us improve the website.	Immediately
AW_VISITOR	Performance cookie to analyze traffic.	1 year

Your privacy

Strictly necessary cookies

Performance cookies

Functional cookies

Targeting and Advertising cookies

More information about Cookies